RESUMO
Clinical and laboratory evaluation of the effectiveness of using intranasal sodium cromoglycate [SCG] 2% in 48 children during their catarrhal stage was studied. The diagnosis of catarrhal reaction was confirmed through proper history taking, clinical examination, x-ray and allergelogical tests. Patients were maintained on sodium cromoglycate 2% spray 4 times daily for 4 weeks. The response to the therapy was evaluated every 2 weeks for the successive 2 months. From the start of therapy. Clinical and laboratory assessment was done according to the degree of the severity of nasal symptoms, mean levels of IGE, eosinophilic count in the sera and mean of positive nasal smears for eosinophils. The results before and after the treatment were presented. This study showed that application of intranasal sodium cromoglycate 2% is effective in decreasing the incidence of recurrent upper respiratory tract infections and controlling the nasal symptoms in catarrhal children. Consequently, this effect helped in avoiding unnecessary surgery. The drug was well tolerated with no side effects throughout the study period